ORM-5029

· Orum Therapeutics USA, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ORM-5029, covering 2025-07-04 to 2025-07-04. Get the full timeline:

Most recent: Clinical Trial Update: Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors [Phase 1]